EGFR and non-small cell lung carcinoma: Patritumumab deruxtecan, an anti-HER3 antibody-drug conjugate (ADC), was investigated in a phase 1 clinical trial (U3-1402) in patients with EGFR-mutant NSCLC who progressed on EGFR TKI [116].